Cargando…

2223. Evaluation of the Microbiology and Clinical Outcomes of Spontaneous Bacterial Peritonitis (SBP) within a US Academic Health System

BACKGROUND: 2021 SBP treatment guidelines recommend empiric therapy with spectra broader than 3(rd) generation cephalosporins (TGC) in patients (pts) at risk for multidrug-resistant organisms (MDOs), including those admitted to ICUs, with nosocomial infections, or with recent hospitalization. This s...

Descripción completa

Detalles Bibliográficos
Autores principales: Chris Parish, P, Taylor, Alex D, Stone, Tyler J, Luther, Vera, Ohl, Christopher, Beardsley, James R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678700/
http://dx.doi.org/10.1093/ofid/ofad500.1845
_version_ 1785150425213698048
author Chris Parish, P
Taylor, Alex D
Stone, Tyler J
Luther, Vera
Ohl, Christopher
Beardsley, James R
author_facet Chris Parish, P
Taylor, Alex D
Stone, Tyler J
Luther, Vera
Ohl, Christopher
Beardsley, James R
author_sort Chris Parish, P
collection PubMed
description BACKGROUND: 2021 SBP treatment guidelines recommend empiric therapy with spectra broader than 3(rd) generation cephalosporins (TGC) in patients (pts) at risk for multidrug-resistant organisms (MDOs), including those admitted to ICUs, with nosocomial infections, or with recent hospitalization. This study aimed to characterize the microbiology and clinical outcomes of SBP in our health system to determine the applicability of these guidelines. METHODS: Setting: 5-hospital academic health system with > 1500 beds. Design: retrospective, observational study. Adult pts from 2010-2022 with ICD 9/10 codes for SBP & liver dysfunction were screened. Pts with concomitant secondary peritonitis were excluded. Study included all pts with culture-positive (CX-pos) SBP and randomly screened pts with culture-negative (CX-neg) SBP to provide a total sample of 80 pts. Primary outcome was % of peritoneal fluid CX with organisms non-susceptible to ceftriaxone (CRO) in CX-pos pts. Secondary outcomes included mortality & effect of MDO risk factors (hospitalization in prior 90 days, ICU admission, or nosocomial infection) on microbiological & clinical outcomes. RESULTS: 49 pts with CX-pos and 31 pts with CX-neg SBP were included. Median age was 59; median MELD score was 25; 26 (33%) were admitted to the ICU. 67 of 80 (84%) total pts had ≥ 1 MDO risk factor; 40 of 49 (82%) in the CX-pos cohort. 8 (16%) isolates were CRO-non-susceptible, 7 in the 40 CX-pos pts with MDO risk factors (17.5%) vs. 1 in the 9 CX-pos pts without risk factors (11%) (p=NS). 49 (61%) pts received initial TGC therapy. Mortality at 30 days & 90 days was 29 (43%) & 40 (60%) and 3 (23%) & 6 (46%) for pts with and without MDO risk factors, respectively. Outcomes based on empiric therapy are summarized in Table 1. [Figure: see text] CONCLUSION: In our facilities, 16% of isolates in CX-pos SBP pts were not susceptible to CRO. There was no significant difference in the number of non-susceptible isolates in pts with and without MDO risk factors. Treatment with broader therapy was not associated with improved outcomes. Within our health system, giving all SBP pts with MDO risk factors broad empiric therapy may not be necessary. Evaluating local microbiologic data may help health systems assess the local applicability of national treatment guidelines. DISCLOSURES: Tyler J. Stone, PharmD, ViiV Healthcare: Employee
format Online
Article
Text
id pubmed-10678700
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106787002023-11-27 2223. Evaluation of the Microbiology and Clinical Outcomes of Spontaneous Bacterial Peritonitis (SBP) within a US Academic Health System Chris Parish, P Taylor, Alex D Stone, Tyler J Luther, Vera Ohl, Christopher Beardsley, James R Open Forum Infect Dis Abstract BACKGROUND: 2021 SBP treatment guidelines recommend empiric therapy with spectra broader than 3(rd) generation cephalosporins (TGC) in patients (pts) at risk for multidrug-resistant organisms (MDOs), including those admitted to ICUs, with nosocomial infections, or with recent hospitalization. This study aimed to characterize the microbiology and clinical outcomes of SBP in our health system to determine the applicability of these guidelines. METHODS: Setting: 5-hospital academic health system with > 1500 beds. Design: retrospective, observational study. Adult pts from 2010-2022 with ICD 9/10 codes for SBP & liver dysfunction were screened. Pts with concomitant secondary peritonitis were excluded. Study included all pts with culture-positive (CX-pos) SBP and randomly screened pts with culture-negative (CX-neg) SBP to provide a total sample of 80 pts. Primary outcome was % of peritoneal fluid CX with organisms non-susceptible to ceftriaxone (CRO) in CX-pos pts. Secondary outcomes included mortality & effect of MDO risk factors (hospitalization in prior 90 days, ICU admission, or nosocomial infection) on microbiological & clinical outcomes. RESULTS: 49 pts with CX-pos and 31 pts with CX-neg SBP were included. Median age was 59; median MELD score was 25; 26 (33%) were admitted to the ICU. 67 of 80 (84%) total pts had ≥ 1 MDO risk factor; 40 of 49 (82%) in the CX-pos cohort. 8 (16%) isolates were CRO-non-susceptible, 7 in the 40 CX-pos pts with MDO risk factors (17.5%) vs. 1 in the 9 CX-pos pts without risk factors (11%) (p=NS). 49 (61%) pts received initial TGC therapy. Mortality at 30 days & 90 days was 29 (43%) & 40 (60%) and 3 (23%) & 6 (46%) for pts with and without MDO risk factors, respectively. Outcomes based on empiric therapy are summarized in Table 1. [Figure: see text] CONCLUSION: In our facilities, 16% of isolates in CX-pos SBP pts were not susceptible to CRO. There was no significant difference in the number of non-susceptible isolates in pts with and without MDO risk factors. Treatment with broader therapy was not associated with improved outcomes. Within our health system, giving all SBP pts with MDO risk factors broad empiric therapy may not be necessary. Evaluating local microbiologic data may help health systems assess the local applicability of national treatment guidelines. DISCLOSURES: Tyler J. Stone, PharmD, ViiV Healthcare: Employee Oxford University Press 2023-11-27 /pmc/articles/PMC10678700/ http://dx.doi.org/10.1093/ofid/ofad500.1845 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Chris Parish, P
Taylor, Alex D
Stone, Tyler J
Luther, Vera
Ohl, Christopher
Beardsley, James R
2223. Evaluation of the Microbiology and Clinical Outcomes of Spontaneous Bacterial Peritonitis (SBP) within a US Academic Health System
title 2223. Evaluation of the Microbiology and Clinical Outcomes of Spontaneous Bacterial Peritonitis (SBP) within a US Academic Health System
title_full 2223. Evaluation of the Microbiology and Clinical Outcomes of Spontaneous Bacterial Peritonitis (SBP) within a US Academic Health System
title_fullStr 2223. Evaluation of the Microbiology and Clinical Outcomes of Spontaneous Bacterial Peritonitis (SBP) within a US Academic Health System
title_full_unstemmed 2223. Evaluation of the Microbiology and Clinical Outcomes of Spontaneous Bacterial Peritonitis (SBP) within a US Academic Health System
title_short 2223. Evaluation of the Microbiology and Clinical Outcomes of Spontaneous Bacterial Peritonitis (SBP) within a US Academic Health System
title_sort 2223. evaluation of the microbiology and clinical outcomes of spontaneous bacterial peritonitis (sbp) within a us academic health system
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678700/
http://dx.doi.org/10.1093/ofid/ofad500.1845
work_keys_str_mv AT chrisparishp 2223evaluationofthemicrobiologyandclinicaloutcomesofspontaneousbacterialperitonitissbpwithinausacademichealthsystem
AT tayloralexd 2223evaluationofthemicrobiologyandclinicaloutcomesofspontaneousbacterialperitonitissbpwithinausacademichealthsystem
AT stonetylerj 2223evaluationofthemicrobiologyandclinicaloutcomesofspontaneousbacterialperitonitissbpwithinausacademichealthsystem
AT luthervera 2223evaluationofthemicrobiologyandclinicaloutcomesofspontaneousbacterialperitonitissbpwithinausacademichealthsystem
AT ohlchristopher 2223evaluationofthemicrobiologyandclinicaloutcomesofspontaneousbacterialperitonitissbpwithinausacademichealthsystem
AT beardsleyjamesr 2223evaluationofthemicrobiologyandclinicaloutcomesofspontaneousbacterialperitonitissbpwithinausacademichealthsystem